2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

4:30PM-6:00PM: Abstract Number: 3057

Objectively Measured Physical Activity and Risk of Knee Osteoarthritis: The Osteoarthritis Initiative

ACR/ARHP Combined Abstract Session: Orthopedics and Rehabilitation

4:30PM-6:00PM: Abstract Number: 3097

Osteoclast Precursor Frequency and Imaging Findings Associated with Arthritis Onset in a Psoriasis Longitudinal Cohort

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV: Psoriatic Arthritis – Clinical

4:30PM-6:00PM: Abstract Number: 3111

Pathogenic T Cell Responses in Systemic Sclerosis Is Shaped By Novel Cytokine Axis in the Microenvironment: A Multidimensional, High Throughput Analysis

T Cell Biology and Targets in Autoimmune Disease - Oral Session

4:30PM-6:00PM: Abstract Number: 3074

Population-Specific Association Between ABCG2 Variants and Tophaceous Disease in People with Gout

Metabolic and Crystal Arthropathies I: Mechanisms of Disease

4:30PM-6:00PM: Abstract Number: 3089

Predicting the Response to TNF Inhibition or B Cell Depletion Therapy from Peripheral Whole Blood Gene Expression Profiles in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 3092

Predictive Factors for Better Outcome of Switching of Biologics for Patients with Rheumatoid Arthritis in Daily Clinical Practice

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 3088

Predictors of Non-Adherence with Anti-Rheumatic Medication in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort

Rheumatoid Arthritis – Clinical Aspects V: Challenges in the Assessment and Management of Established RA

4:30PM-6:00PM: Abstract Number: 3081

Prognostic Factors of Death in a Cohort of 116 Adults with Hemophagocytic Syndrome: Impact of Underlying Disease and Laboratory Parameters

Miscellaneous Rheumatic and Inflammatory Diseases II

4:30PM-6:00PM: Abstract Number: 3077

Quiescence in Active and Inactive Non-Infectious, Intermediate, Posterior, or Panuveitis in Patients Treated with Adalimumab

Miscellaneous Rheumatic and Inflammatory Diseases II

4:30PM-6:00PM: Abstract Number: 3110

Rab4A Is Required for Development of Tregs, Restricts Antiphospholipid Antibody Production and Pro-Inflammatory Expansion of Macrophages and Neutrophils, and Blocks Pristane-Induced Intra-Alveolar Hemorrhage in a Mouse Model of SLE

T Cell Biology and Targets in Autoimmune Disease - Oral Session

4:30PM-6:00PM: Abstract Number: 3071

Recombinant Human Proteoglycan-4 (rhPRG4) Inhibits Monosodium Urate (MSU) Crystal Phagocytosis By Human Macrophages and Resultant Inflammatory Response

Metabolic and Crystal Arthropathies I: Mechanisms of Disease

4:30PM-6:00PM: Abstract Number: 3109

Regulatory T Cells Deficient in Protein Phosphatase 2A Lose Suppressive Function and Convert to an Effector Phenotype

T Cell Biology and Targets in Autoimmune Disease - Oral Session

4:30PM-6:00PM: Abstract Number: 3105

Relationships Between a Serum Biomarker of B Cell Differentiation and B Cell Activating Factor Suggest Possible Distinct Pathways of Response to Rituximab in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 3080

Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg

Miscellaneous Rheumatic and Inflammatory Diseases II

4:30PM-6:00PM: Abstract Number: 3066

Risk of Incident Cancer with Biologic and Tofacitinib Therapy in Rheumatoid Arthritis

Epidemiology and Public Health II: Obesity, Cancer and Mortality

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].